Full Press Release Details
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate.
ALT
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Key Takeaway: Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate